Zomedica stock holds after Q2 2026 call
Published on 08/29/2026 at 22:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Zomedica Corp. (CA98959U1084) is in view after its Q2 2026 earnings call on August 28, 2026, with current market coverage showing OTC trading at $0.0820 and a 5-day change of -3.53%.
Latest quarter
The same transcript coverage points to a recent earnings update, while analyst-style forecast pages continue to show no broad consensus base for the name. That mix matters for Zomedica stock because the quarter and the market quote are now the main data points investors can compare.
For context, the latest market snapshot in the result set also shows a year-to-date move of -19.41%, which keeps the stock deep in micro-cap territory at a price of $0.0820. The quantified comparison is straightforward: the 5-day move of -3.53% sits inside a year-to-date decline of -19.41%.
Trading backdrop
OTC Markets is the only venue visible in the current quote snapshot, and the price action has stayed centered on fractions of a dollar. That keeps attention on liquidity, not on a large re-rating, because even small changes in cents can move the percentage change sharply.
Product angle
Truforma remains the representative product line for Zomedica, and the business still centers on veterinary diagnostics and related consumables. For investors, that means the story is tied to adoption and repeat usage rather than a broad consumer brand.
Market level
Zomedica stock was last quoted at $0.0820 on August 28, 2026, with the latest snapshot also showing a 5-day change of -3.53% and a year-to-date move of -19.41%.
Fact box
Company: Zomedica Corp.
ISIN: CA98959U1084
Ticker: ZOMDF
Exchange: OTC Markets
Price (as of August 28, 2026, 9:55 p.m. ET): $0.0820 USD
Market cap: not stated in the cited sources
Sector / Industry: Health Care / Medical Devices
Index membership: not stated in the cited sources
